^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
Excerpt:
...Patients with HER2 positive； 3....
Trial ID:
Source:
Title:
450P - Efficacy and safety of pyrotinib-based therapy in HER2-positive metastatic colorectal and gastric cancer: A retrospective study
Published date:
09/13/2021
Excerpt:
In the subgroup analysis, ORR and DCR were 33.3% (5/15) and 66.7% (10/15) in CRC, 18.2% (2/11) and 54.5% (6/11) in GC, respectively. The median DOT was similar in CRC (6.3 months) and GC (5.8 months).,,,Pyrotinib-based therapy demonstrates promising effects in HER2-positive metastatic colorectal and gastric cancer and prospective clinical trial is warranted to confirm its activity in patients failed to first-line therapy.
Source:
Title:
1511P - A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer
Published date:
09/14/2020
Excerpt:
Total 25 pts with HER-2 positive/mutations were enrolled….21 (84.0%) pts received 400 mg pyrotinib once daily as initial dose, 2 (8%) pts received 320 mg, 2 (8%) pts received 160 mg. Total 23 pts were eligible for efficacy evaluation, 12 pts achieved PR (4 pts with lung cancer, 4 pts with gastric cancer, 2 pts with colorectal cancer, 2 pts with thymic cancer), 9 pts were SD and 2 pts were PD. The ORR was 52.2% and the DCR was 91.3%. The mPFS was 3.5 months (95%CI: 2.2-5.0 months), mOS was 9.6 months (95%CI: 4.4 months-NR)....The retrospective study showed that pyrotinib showed good efficacy and safety in patients with HER-2 positive/mutation solid tumors,...
